Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07213076) titled 'Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib' on Oct. 1.
Study Type: Observational
Primary Sponsor: AstraZeneca
Condition:
Non-small Cell Lung Cancer
Recruitment Status: Recruiting
Date of First Enrollment: July 4, 2025
Target Sample Size: 350
Countries of Recruitment:
Australia
To know more, visit https://clinicaltrials.gov/study/NCT07213076
Published by HT Digital Content Services with permission from Health Daily Digest....